Phosphaplatin Bone-Targeting Compounds for Blood Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone and blood cancers, such as multiple myeloma, are challenging due to the need for chemotherapy agents to accumulate in cancerous bone tissues, and existing platinum-based drugs like cisplatin and carboplatin have limitations in efficacy and selectivity, especially for cancers metastasizing to bone.
Innovation Solution
Phosphaplatin compounds, particularly pyrophosphato-platinum complexes like (R,R)-1,2-cyclohexanediamine-(dihydrogen pyrophosphato) platinum(II) (PT-112), are administered to accumulate in bone tissues, effectively reducing M-spike levels in multiple myeloma models and treating various bone and blood cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard platinum compounds (cisplatin, carboplatin, oxaliplatin) are used for treating bone blood cancers, then some therapeutic effect is achieved, but the compounds show poor solubility and/or poor stability and/or insufficient efficacy
Solution Approach 1:
The patent modifies the chemical parameters of platinum compounds by introducing phosphaplatin structures with specific phosphorus-containing ligands (such as phosphines and phosphonates) to alter solubility and stability properties while maintaining or enhancing anticancer activity. This is evident in the development of compounds with formula (I) where varying R1-R6 substituents optimize both therapeutic efficacy and physicochemical properties.
Solution Approach 2:
The invention creates composite platinum compounds combining phosphorus-containing organic ligands with platinum centers, forming new hybrid structures that integrate the benefits of both metal coordination chemistry and phosphorus-based stabilizing groups. These composite structures address the limitations of conventional platinum agents by incorporating multiple functional moieties into a single molecular entity.
2Reliability
If conventional platinum compounds are administered, then treatment is provided, but they cause severe side effects including nephrotoxicity, neurotoxicity, and ototoxicity
Solution Approach 1:
The patent employs phosphorus-containing ligands that selectively bind to and neutralize reactive oxygen species and free radicals, converting the harmful oxidative stress that causes toxicity into a protective effect. The phosphine and phosphonate groups act as radical scavengers, protecting healthy tissues from platinum-induced oxidative damage while maintaining anticancer efficacy.
Solution Approach 2:
The phosphorus-containing ligands serve as intermediary protective groups that mediate between the platinum active site and biological tissues. These ligands act as steric and electronic buffers, reducing the direct interaction between the platinum center and healthy cells, thereby minimizing toxic effects on kidneys, nerves, and ears while preserving the compound's ability to target cancer cells.
3Adaptability or versatility
If existing platinum compounds are used, then some cancers are treated, but they are ineffective against certain cancers including bone blood cancers
Solution Approach 1:
The patent introduces specific local modifications to the platinum compound structure by placing particular phosphorus-containing groups at strategic positions around the platinum center. These localized structural features create compounds with enhanced affinity for bone marrow and bone blood cancer cells, providing targeted efficacy for this specific cancer type while maintaining broader applicability.
Solution Approach 2:
The invention segments the platinum compound into distinct functional modules: a platinum core for anticancer activity, phosphorus-containing ligands for stability and solubility, and specific substituents for bone blood cancer targeting. This modular segmentation allows optimization of each component's function, enabling the compound to effectively treat bone blood cancers while retaining versatility for other cancer types.
Data Source
Figure 1~2B
Figure 3~5
Figure 6
AI summary
Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes ("phosphaplatin compounds"), especially (R,R)-l,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or "PT-112"), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.